Surgical oncology evidence belongs to every physician treating cancer. The medical oncologist sequencing therapy needs to know what's resectable. The radiation oncologist planning a course needs to know what margins were achieved. The primary care physician explaining options to a newly diagnosed patient needs to know what surgical care actually involves. Today we're partnering with the Society of Surgical Oncology to bring @SocSurgOnc clinical content and educational resources into OpenEvidence. The partnership also launches the SSO Innovator Grant, a 24-month research award supporting surgeon-led work on AI-enabled medical knowledge and clinical decision support in surgical oncology. Applications open Summer 2026. The body of evidence in surgical oncology is growing faster than any single surgeon can track. The point of the partnership is to put that evidence in front of every physician taking care of a cancer patient, in the moment they need it.

Memorial Sloan Kettering opening its precision oncology data to physicians nationwide through OpenEvidence. Today's Forbes has the story. @MSKCancerCenter has spent years building the world's most detailed map of which cancer mutations respond to which treatments. Until now, you had to be treated at MSK to benefit from it. Soon, an oncologist in a small practice in Montana will see the same evidence as a subspecialist in Manhattan, at the moment it matters, for the patient in front of them. More patients getting the right treatment the first time, wherever they live. Read full article here

🚨 This may be the most consequential oncology study of 2026. Yes, on par with daraxonrasib. At #ASCO26# we highlighted the 5-year KEYNOTE-942 data for the individualized mRNA cancer vaccine intismeran + pembrolizumab in resected high-risk melanoma. And the numbers were 👀 RFS HR 0.51 5-year RFS: 68.8% vs 49.1% DMFS HR 0.41 OS HR 0.47 (still immature) Amazing data. But 157 patients. Phase IIb. The big question: does it hold up in phase III? Apparently, yes. 🔥 INTerpath-001 randomized 1,137 patients with resected stage IIB-IV melanoma to intismeran + pembrolizumab vs pembrolizumab alone. At the prespecified interim analysis: ✅ RFS met ✅ DMFS met ✅ Statistically significant AND ✅ No new safety signals We don’t have the HRs yet. So some restraint until we see the actual data (also this is a press release, so grain of salt) But why is this such a big deal? Because this isn’t really about melanoma. 🧬 Sequence YOUR tumor 🎯 Identify YOUR neoantigens 💉 Manufacture a vaccine specifically for YOUR cancer 🦠 Train YOUR immune system to recognize it And now that approach has succeeded in a randomized phase III trial. This is actually personalized. And if this platform works across tumor types, the implications are enormous. Daraxonrasib may change how we treat RAS-driven cancers. INTerpath-001 may change how we think about cancer vaccines altogether. 2026 has been an amazing year for oncology advances. 🔥 @OncoAlert @Onco_Nexus @TheGutOncLab

Today, Memorial Sloan Kettering Cancer Center (MSK) and OpenEvidence announced a partnership to advance precision oncology. This partnership includes integration of OpenEvidence within MSK’s Epic workflow, and bringing OncoKB™, MSK's precision oncology knowledge base, directly into OpenEvidence for its broader use by physicians outside of @MSKCancerCenter. “AI has the potential to fundamentally change how we translate an increasingly complex and rapidly expanding body of knowledge into better decisions for patients,” – Anaeze Offodile, M.D., Chief Strategy Officer at MSK. Full press release:

Congrats to @TimothyJBrownMD for leading this insightful editorial on “Patient-reported outcomes and targeted therapeutic escalation in NRG Oncology/RTOG 1010: When intensification fails to translate to improved outcomes” published in @JournalCancer

Today we announced that three abstracts on intismeran autogene, our investigational mRNA-based individualized neoantigen therapy, have been accepted for presentation at the European Society for Medical Oncology (@myESMO) Congress 2026, which will be held October 23–27 in Madrid, Spain. Read more:  #ESMO26#